Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20067231HPVENSG00000096968.14protein_codingJAK2YesNo3717O60674
TVIS20066328HPVENSG00000096968.14protein_codingJAK2YesNo3717O60674
TVIS20021822HPVENSG00000096968.14protein_codingJAK2YesNo3717O60674
TVIS20021828HPVENSG00000096968.14protein_codingJAK2YesNo3717O60674
TVIS20013251HPVENSG00000096968.14protein_codingJAK2YesNo3717O60674
TVIS20021829HPVENSG00000096968.14protein_codingJAK2YesNo3717O60674
TVIS20026486HPVENSG00000096968.14protein_codingJAK2YesNo3717O60674
TVIS20021821HPVENSG00000096968.14protein_codingJAK2YesNo3717O60674
TVIS20021824HPVENSG00000096968.14protein_codingJAK2YesNo3717O60674
TVIS20063911HPVENSG00000096968.14protein_codingJAK2YesNo3717O60674
TCGA Plot Options
Drug Information
GeneJAK2
DrugBank IDDB12500
Drug NameFedratinib
Target IDBE0002408
UniProt IDO60674
Regulation Typeinhibitor
PubMed IDs21220608; 27473820
CitationsPardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A: Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011 Mar 1;29(7):789-96. doi: 10.1200/JCO.2010.32.8021. Epub 2011 Jan 10.@@Roskoski R Jr: Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016 Sep;111:784-803. doi: 10.1016/j.phrs.2016.07.038. Epub 2016 Jul 26.
GroupsApproved; Investigational
Direct ClassificationBenzenesulfonamides
SMILESCC1=CN=C(NC2=CC=C(OCCN3CCCC3)C=C2)N=C1NC1=CC=CC(=C1)S(=O)(=O)NC(C)(C)C
Pathways
PharmGKBPA166280361
ChEMBLCHEMBL1287853